Board summary
Key figures
37,220
Registered population
57.4% aged 18–64
22.1%
Aged 65+
ICB 19.9% · England 17.9%
10.3%
Ethnic minority (non-White)
3.3% Asian · England 9.6%
15.9%
In IMD quintile 1
ICB 17.1% · England 21.0%
~5,796
Core20 residents (est.)
Resident basis; registered basis ~5,914 · see page 3
7,474
Hypertension register
+29.17% in 3 yrs · England +5.60%
360
SMI register
39.5% of Sevenoaks'
759
COPD register
Reviews -5.71% in 3 yrs
Forecast to 2030
12,893
Hypertension patients, 2030
+5,419 on today
55.6%
QRISK ≥20% on statins, 2030
-5.44pp over 3 yrs
6.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Blood pressure control trails rapid register growth.
Hypertension control is 66.9% (England 70.3%) despite +29.2% register growth, while QRISK lipid therapy fell 7.7%, which may reflect review backlogs.
Asthma and COPD annual reviews trail England.
Asthma reviews fell 10.1% to 53.2% (England 65.7%) and COPD reviews are 62.2% (England 76.4%), which could reflect recall capacity pressures.
Heart failure and mental health checks rose.
Heart failure reviews rose +88.5% to 86.3% (England 78.5%) and SMI blood pressure checks rose +22.6 pp over 2023 to 2025.
Population, age and ethnicity
Older adults comprise 22.1% of patients, exceeding borough, ICB, and England benchmarks
Across 37,220 registered patients, 22.1% (8,225) are aged 65+, above Sevenoaks (19.7%), NHS Kent and Medway ICB (19.9%), and England (17.9%). Children aged 0–17 represent 20.5% (7,642; Sevenoaks 21.7%, ICB 20.7%, England 19.6%). Practice scale is uneven: River Darent Medical Group has 12,258 patients (25.2% aged 65+), while Swanley Medical Practice has 24,962 (20.6% aged 65+). Census usual-resident data show 89.7% White (Sevenoaks 92.1%, ICB 88.6%, England 81.1%). Unverified ONS projections indicate 1.8% list growth to 2030 (Sevenoaks 2.9%, ICB 6.0%, England 2.3%). A higher older-adult proportion across both practices could indicate elevated frailty demand, testable through practice clinical register.
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Sevenoaks local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Sevenoaks LA) | 2,262 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 81.8% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 57.7% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Sevenoaks LA) | 1,154 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Sevenoaks LA) | 15.5 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 15.9% across the PCN and concentrates in Swanley Medical Practice
The PCN Core20 cohort is 15.9%, above Sevenoaks (4.4%) but below NHS Kent and Medway ICB (17.1%) and England (21.0%), with weighted practice shares reconciling at 15.9%. Deprivation divides sharply across practices: Swanley Medical Practice records a 22.8% Core20 share (an estimated 5,701 patients), whereas River Darent Medical Group records 1.7% (an estimated 213 patients), creating a 21.1 pp spread. Concentration of estimated Core20 patients in Swanley Medical Practice indicates uneven deprivation demand, which practice-level clinical audits can test.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
360
SMI register
0.96% recorded prevalence
177
Learning disability register
0.47% recorded prevalence
7
Care homes, 373 beds
In the PCN catchment
8.7%
Provide unpaid care
Sevenoaks, Census 2021
Registers record 177 learning disability patients (0.5%; Sevenoaks 0.4%, ICB 0.6%, England 0.6%) and 360 severe mental illness patients (1.0%; Sevenoaks 0.8%, ICB 0.9%, England 1.0%). Catchment services include 7 care homes (373 beds) and 0.8% Gypsy or Irish Traveller residents (Sevenoaks 0.4%, ICB 0.3%, England 0.1%). Higher Gypsy or Irish Traveller presence may reflect distinct community access needs, testable via practice registration audits.
Severe mental illness: physical health checks
SMI blood pressure checks reached 81.5% (Sevenoaks 85.2%, England 83.4%), rising +22.6 pp over 2023 to 2025 (England +4.4 pp). Smoking cessation support offered to patients with certain conditions was 88.7% (England 94.2%; Swanley Medical Practice 87.0%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,474
Hypertension register
+29.17%
Register growth, 3 yrs
Sevenoaks +14.96% · England +5.60%
+1.93pp
BP control, under 80
≤140/90 · +4.52pp aged 80+
+5,419
More patients by 2030
Forecast 12,893 (33.41%)
Hypertension case-finding and control
Hypertension prevalence is 20.0% (7,474 patients), higher than Sevenoaks (16.6%), NHS Kent and Medway ICB (16.2%), and England (15.2%), having grown +29.2% over 2023 to 2025 (England +5.6%). However, patients treated to target reach 66.9%, trailing England's 70.3%. In patients aged under 80, control to <= 140/90 mmHg is 62.8% (England 67.8%), with Swanley Medical Practice at 60.9% and River Darent Medical Group at 66.4%. In those aged 80 and over, control is 76.8% (England 81.2%). Crude prevalence does not reflect age-adjusted need, and denominators include personalised care adjustments. Lower control rates in patients aged under 80 may reflect review backlogs or titration delays, unverified locally and testable by recall audit.
Lipids and statins
Patients with QRISK ≥ 20% receiving lipid-lowering therapy stand at 65.2% (England 63.6%, Sevenoaks 60.3%), but this fell 7.7% over 2023 to 2025 (England +6.2%). Recent contraction could reflect recall gaps, unverified locally and testable by high-risk patient search review.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 63,640 | £1.90 | £1.90 | £1.86 | £120,916 |
| Cardiovascular (all), 2025 | 84,074 | £4.77 | £3.57 | £3.33 | £401,033 |
In 2026, lipid-regulating drugs cost £1.90 per item across 63,640 items, compared to £1.86 in England, £1.68 in Sevenoaks, and £1.90 in NHS Kent and Medway ICB. This represents £2,546 more than at England's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−10.13%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+3.30%
Asthma prevalence, PCN 3-yr % change
Asthma reviews fell 10.1% over 2023 to 2025 (England +4.4%) to 53.2% (England 65.7%, Sevenoaks 58.8%), leaving about 950 patients unreviewed across a register of 2,023. COPD reviews fell 5.7% (England +2.8%) to 62.2% (England 76.4%, Sevenoaks 68.5%) on a register of 759 patients, which contracted 7.1% (England +2.6%). COPD review coverage is 58.6% at Swanley Medical Practice and 70.3% at River Darent Medical Group. Falling reviews could reflect recall capacity constraints, unverified locally and testable by search review.
Cancer register and children's immunisation
The cancer register records 1,814 patients (4.9% vs England 3.8%). In Q1 2025/26, MMR1 coverage at 24 months was 87.0% (below the 95.0% target by 8 pp; England 88.3%), and age-5 4-in-1 booster coverage was 87.2% (below target by 7.8 pp; England 80.9%). Age-5 MMR1 (94.2%) exceeded MMR2 (90.7%) by a 3.5 pp dose difference. Dose drop-off could reflect call-recall gaps, unverified locally and testable by list audit.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
Across NHS Kent and Medway ICB in 2022, 55.6% of cancers were diagnosed at stage 1 or 2 (4,661 of 8,384 staged cancers), in line with England (55.3%) but below the 75.0% national ambition by 2028 by 19.4 pp. Known-stage data covered 63.6% of registered cancers (8,384 of 13,189; England 67.0%). These figures describe the wider system rather than PCN performance. Locally, PCN cervical screening coverage aged 25-49 is 70.9% (Sevenoaks 73.4%, England 66.8%) and breast screening coverage is 69.4% (Sevenoaks 73.5%). Lower screening uptake than the borough average may delay early detection, making primary care call-recall coordination the principal operational priority.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), Dartford and Gravesham NHS Trust met the cancer 62-day referral to treatment standard for 63.6% of pathways (65.5 of 103), trailing the 85.0% standard by 21.4 pp, below NHS Kent and Medway Integrated Care Board (75.9%), King's College Hospital NHS Foundation Trust (70.1%) and England (71.2%). Conversely, the trust achieved 78.1% on the 28-day faster diagnosis standard (standard 75.0%) and 97.5% on the 31-day standard (standard 96.0%). Diagnostic waits of 6+ weeks across all tests were 8.4% (England 23.1%). System treatment delays reinforce the need for robust primary care referral safety netting and fast-track tracking.
| Pathways within standard (%) | Dartford and Gravesham | King's College | Kent and Medway ICB | England |
|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 78.14 | 80.68 | 76.78 | 79.32 |
| 31-day treatment (96%) | 97.48 | 96.68 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 63.59 | 70.15 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Dartford and Gravesham | Kent Health | King's College | England |
|---|---|---|---|---|
| MRI | 0.36 | — | 21.22 | 21.40 |
| CT | 2.08 | — | 22.60 | 9.92 |
| Echocardiography | 3.90 | — | 14.39 | 28.48 |
| Colonoscopy | 0.40 | — | 41.81 | 30.83 |
| Gastroscopy | 0.00 | — | 35.98 | 29.02 |
| All 15 DM01 tests | 8.37 | 27.49 | 19.15 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). In June 2026 (provisional), Kent residents accounted for 265,905 community care activities and 210,170 contacts across 60,605 patients, with 59,360 referrals. Across NHS Kent and Medway Integrated Care Board, activity reached 297,595 activities and 254,055 contacts across 72,060 patients. Contacts with adults aged 65+ represented 65.8% of Kent residents' contacts (138,250 of 210,170). Substantial community contact volume among older residents highlights an active pathway for local multidisciplinary support.
Practice variation and patient experience
Overall patient experience varies by 13.2 pp while phone access trails England
In 2025/26, QOF clinical achievement was 98.5% at Swanley Medical Practice and 98.4% at River Darent Medical Group (England 97.1%). For vaccination and immunisation, Swanley Medical Practice achieved 38.3% and River Darent Medical Group achieved 32.5%, trailing England (55.2%) across a 5.8 pp spread. Shared vaccination shortfalls indicate an immunisation delivery gap despite high clinical points.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Swanley Medical | 112 | 22.8 | 35.9% | 73.6% | 73.4% |
| River Darent | 108 | 1.7 | 41.5% | 73.1% | 60.2% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Dementia registers fell 5.6% over three years while heart failure reviews rose +88.5%
Over 2023 to 2025, asthma reviews fell 10.1% (England +4.4%) and QRISK ≥ 20% lipid therapy fell 7.7% (England +6.2%). Recorded dementia prevalence fell 5.6% (England +6.0%) and COPD registers fell 7.1% (England +2.6%). By contrast, heart failure reviews rose +88.5% (England +8.7%) and severe mental illness blood pressure checks increased +22.6 pp (England +4.4 pp). These divergent trends may reflect pathway-specific recall focus or coding practices, unverified locally and testable by clinical audit.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Asthma reviews
QRISK statin treatment
Dementia register
COPD register
COPD reviews
Heart failure reviews
BP check (SMI)
BMI record (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Sevenoaks | Asset | PCN | Sevenoaks |
|---|---|---|---|---|---|
| Care homes (catchment) | 7 (373 beds) | n/a | Schools (catchment) | 54 | n/a |
| Children's centres | 3 | 5 | Places of worship | 33 | 86 |
| Libraries | 3 | 11 | Day centres (VCS) | 8 | 11 |
| Children and young people (VCS) | 1 | 2 | Carers support groups (VCS) | n/a | 3 |
| Primary schools (LA maintained) | 8 | 24 | Primary academies | 7 | 12 |
| Special schools | n/a | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension control and lipid review
Across 7,474 hypertensive patients (20.0%), BP control is 66.9% (England 70.3%; under 80s 62.8% vs 67.8%, with Swanley Medical Practice at 60.9% and River Darent Medical Group at 66.4%). QRISK ≥ 20% lipid therapy (65.2%) fell 7.7% (England +6.2%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Asthma and COPD annual review recall
Asthma reviews fell 10.1% to 53.2% (England 65.7%, +4.4%), leaving 947 unreviewed of 2,023 patients. COPD reviews fell 5.7% to 62.2% across 759 patients (England 76.4%, +2.8%; Swanley Medical Practice 58.6%, River Darent Medical Group 70.3%). Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Dementia and learning disability register audit
The dementia register (347 patients, 0.9%) fell 5.6% over 2023 to 2025 (England +6.0%; gap range -56 to +15). Learning disability prevalence is 0.5% (177 patients vs England 0.6%; gap range -27 to +42). Low cost, quick to run.
Evidence base: dementia diagnosis rates lag in deprived and minority ethnic populations and in care homes; the register is the cohort for diagnosis-rate improvement and the annual dementia review, and diagnosis and post-diagnostic support delay care-home entry.
Policy anchor: national dementia diagnosis-rate ambition of 66.7%; 95% of people with complex needs to have an agreed care plan by 2027.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Frailty and complex care planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Differentiated Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Condition smoking cessation audit (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension recall and titration (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Childhood immunisation recall overhaul (p6) | MMR dose 1 coverage at 24 months | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Hypertension control and lipid review (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 2 · Asthma and COPD annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD register | Core20PLUS5 respiratory | PCN & Practice |
| Option 3 · Dementia and learning disability register audit (p12) | Dementia register · Dementia: QOF prevalence · Learning disability register | 66.7% diagnosis ambition · 95% care plan 2027 · 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
